Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis.

Mohamed M HassaneinRachid MalekSaud Al SifriRakesh Kumar SahayMehmet Akif BuyukbeseKhier DjaballahLydie Melas-MeltInass Shaltout

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)

Concomitant iGlarLixi and SGLT-2i therapy with or without other OADs was demonstrated to be safe in adults with T2D during Ramadan fast, with a low risk of hypoglycemia and improvements in glycemic outcomes.

Keyphrases

type diabetes
glycemic control
randomized controlled trial
systematic review
blood glucose
insulin resistance
metabolic syndrome
adipose tissue
data analysis